Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 26;45(12):7094–7105. doi: 10.1093/nar/gkx423

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 7. — The comparison between the pathways enrichment in leukemia/lymphoma, sarcoma and solid tumors. There is a different pattern of the enrichment. The pathways enriched in leukemia are: Wnt Signaling (P-value = 2.24E-16), p53 pathway (P-value = 1.95E-10), Notch signaling (P-value = 2.95E-09), EGFR signaling (P-value = 2.31E-08), DNA replication (P-value = 9.81E-07), TGF-β signaling (P-value = 1.95E-06) and CCKR signaling (P-value = 2.30E-06). The pathways enriched in sarcoma are: Notch signaling (P- value = 8.48E-14), TGF-β signaling (P-value = 3.01E-10), p53 pathway (P-value = 7.31E-09), Wnt signaling (P-value = 2.32E-08) and CCKR signaling (P-value = 8.48E-07). The pathways enriched in solid tumors are: FGFR signaling (P-value = 6.32E-15), EGFR signaling (P-value = 2.13E-11), TGF-β signaling (P- value = 2.20E-07), Wnt signaling (P-value = 2.24E-06) and Notch signaling (P-value = 8.48E-06).